Abstract Extramedullary relapses after allogeneic stem cell transplantation, especially within the central nervous system (CNS), are not only difficult to treat but also associated with poor outcome. Although the graft-versusleukemia (GvL) effect is nowadays accepted and well documented, it remains controversial whether one can make use of GvL effects in immunological-restricted areas ("sanctuary sites") like the central nervous system. Here, we present data of three hematological patients suffering from isolated CNS relapse of CML or AML after allogeneic stem cell transplantation. Patients received in addition to chemotherapy intrathecal infusions of donor lymphocytes by CD14 depletion of peripheral blood mononuclear cells from the correspondent allogeneic donor. Referring to an observation period of maximum 17 months no immediate or delayed side effects could be detected.
Introduction
Due to a longer survival after allogeneic stem cell transplantation (allo SCT) as well as by enlarged treatment options, e.g., reduced-intensity conditioning regimens, treatment of evolving relapses after allo SCT is more and more challenging. Thereby, extramedullary (EM) relapses play an important role as they occur more frequently after allo SCT compared with non-transplant leukemia treatments. They can be accompanied by a bone marrow relapse but also occur separately [1] . The median time to EM relapse is usually longer compared with bone marrow relapse [1] . Allotransplanted patients suffering from graftversus-host disease (GvHD) show a significant reduction of bone marrow relapses compared with patients without GvHD, which is attributed to the coexistent graft-versusleukemia (GvL) effect [2] . However, the rate of EM relapses seems to be independent on the rate of GVHD [3, 4] . A possible explanation might be the concept of the so-called "sanctuary" sites for chemotherapy. These sites also might represent immunologically privileged organs, where there is only a slight GvL reaction if any at all [5, 6] . This hypothesis is supported by the fact that there is apparently no influence on the EM relapse after systemic infusion of donor lymphocytes (DL) and subsequent occurrence of GvHD [7, 8] .
Among the EM relapses, the affection of the central nervous system (CNS) implicates additional treatment problems resulting in a poor outcome. Limiting factors of an effective treatment are mainly due to the extended neurotoxicity and the restricted disposability of agents acting effectively across the blood-brain barrier [9, 10] . To enlarge hitherto-used therapeutic options (including local irradiation, systemic cytostatic therapy, and second allo SCT [11] ) application of DL directly into the cerebrospinal fluid (CSF) is an obvious possibility. But so far this procedure has not been performed in the case of a leukemic CNS relapse after allo SCT. This appears to be of special relevance in the situation of isolated CNS relapse with full chimerism in bone marrow and blood. In our study, we infused DL intrathecal in three patients suffering from isolated leptomeningeal relapse after allo SCT, having no other established conventional treatment option.
Patients and methods

Patients and treatment
After diagnosis of leukemic meningeosis in three patients (Table 1) after allo SCT we started treatment with systemic high-dose cytarabine chemotherapy followed by intrathecal applications of DL as an induction therapy. Thereafter, in intervals of one up to three weeks we continued the application of intrathecal DL as consolidation therapy in escalating doses. Treatment was changed when either no leptomeningeal remission could be achieved or the disease progressed. Time and doses of the intrathecal applications are displayed in Fig. 1a .
Patients gave written informed consent to this individualized treatment plan including possible life-threatening side effects like encephalitis, meningitis, cerebral GvHD or other infectious complications leading to death.
Cell preparation
Under GMP conditions, a monocyte-free CD14 depleted T cell product from donor PBMC gathered in steady state was generated by negative immunomagnetic selection using a CliniMACS cell selector device (Miltenyi Biotec, Bergisch Gladbach, Germany). Counted amounts of 1×10 6 cells per vial (containing approximately 60% CD3+cells) were stored in liquid nitrogen for repeated injections and administered by a lumbar puncture. The table shows the characteristics of the three patients CML chronic myeloid leukemia, AML acute myeloid leukemia, GvHD graft-versus-host disease, BM bone marrow, ITT intrathecal triple therapy, EM extramedullary, Flu fludarabine, Treo treosulfane, TBI total body irradiation, Bu busulfan, Cy cyclophosphamide, Mel Melphalane, Outcome: CR complete remission defined by CSF clearance (cytology, flow cytometry, and molecular genetics; no bone marrow relapse and major clinical improvement), PR partial remission defined by at least 50% CSF clearance (no bone marrow relapse and clinical improvement), PD progressive disease defined by increase of CSF cell count (BM relapse or new EM relapses)
Analysis of the cerebrospinal fluid CSF was taken at each time point of DL application and was examined regarding cell count, cell cytology and immunphenotypical investigations performed by flow cytometry. Molecular genetic analysis of the CSF and bone marrow was done for quantitative analysis of the hematopoietic chimerism and in the case of the chronic myeloid leukemia (CML) patient additionally for the BCR-ABL fusion transcript using conditions according to the EAC recommendations with the ΔΔCT method and bGUS as housekeeping gene [12] . Chimerism analysis was performed as previously described [13] . At the beginning of the treatment as well as in the follow-up period, cerebral imaging was accomplished by MRI or CT scans. Routine neuroclinical examinations were performed to monitor neurological disorders.
Results and discussion
Patient 1, who was 15 months after the diagnosis of an acute myeloid leukemia (AML) and who underwent allografting from his identical brother 1 year ago, was admitted to our hospital representing symptoms like nausea, vomiting and progressing somnolence. A cerebral CT scan showed fulminant cerebral and cerebellar edema. Through lumbar puncture the diagnosis of a leptomeningeal relapse of the AML was stated and immediate treatment was started with systemic high-dose cytarabine (3 g/m 2 every 12 h for 3 days, total of six doses). After clinical improvement and marked reduction of the cerebellar edema we added a second course of systemic highdose cytarabine followed by intrathecal application of monocyte-free DL. The patient received 1×10 6 CD14-negative DL and no treatment-related acute toxicity was observed. Based on this observation we continued the treatment over a period of 90 days. In total, the patient received seven intrathecal DL infusions in escalating doses of up to 10×10 6 T cells (Fig. 1a) . The patient could be treated outpatient in good general condition with disappearance of neurologic symptoms. Nevertheless, the donor chimerism in the CSF decreased during the treatment with DLI and in the later clinical follow-up course the patient not only represented clinical signs of leptomeningeal progress (radicular pains) but also slowly increasing CSF cell numbers. In consequence, the treatment was changed to intrathecal infusions of liposomal cytarabine leading to another remission in the CSF. Two hundred and seventy days after the first infusion of DL the patient relapsed in the bone marrow accompanied by another leptomeningeal relapse necessitating additional treatment including systemic chemotherapy, a second allo SCT from the same donor and, after development of extramedullary chloroma, local irradiation. The patient died 18 months after diagnosis of the first leptomeningeal relapse of the AML with progressive paravertebral chloroma. Besides, transient delay of CSF cell number rise and control of neurological symptoms, a lasting efficacy of the CD14 depleted adoptive intrathecal cell donations could not be stated in this patient, but we could not observe any side effects during an observation time of 18 months.
Patient 2 was diagnosed with CML in 1996. Allo SCT from the brother was performed in the same year. Inbetween 11 years, two relapses of the bone marrow were successfully treated with DLIs, a third relapse by increasing the dose of imatinib. During this time she developed neurologic symptoms like nausea, headache and photophobia. At the time point of the leptomeningeal relapse, confirmed by CSF cytology and flow cytometry, no hematologic bone marrow relapse was present. After the initial treatment with intrathecal methotrexate (15 mg), cytarabine (40 mg), and dexamethasone (4 mg) an early progress with facial nerve paresis appeared. A systemic high-dose therapy with cytarabine (see above) was started and followed by a first intrathecal infusion of 1×10 6 T cells. From then on we infused DL in escalating doses up to 6×10 6 cells almost weekly (Fig. 1a) . Regarding the cell count in the CSF, the patient showed a good response with a decrease of blasts in the CSF and a complete reconstitution of the donor chimerism in the CSF (Fig. 1b) . Furthermore, less than 10 −2.3 BCR-ABL transcripts referring to a time point 36 days after diagnosis of the leptomeningeal relapse could be detected in the CSF 40 days later. Because of the poor prognosis and the experimental approach we added nilotinib (2×200 mg/day) to the treatment 70 days after diagnosis. The patient achieved complete remission in the CSF for 15 months as well as a major molecular remission in the bone marrow. The neurological symptoms were completely resolved. As a consequence, intrathecal DL application was stopped after eight applications. Seventeen months after initial diagnosis of the leptomeningeosis the patient presented symptoms of hypoacusis, ataxia and cephalgia. In the cerebral imaging intraparenchymal tumors in the left hippocampus and frontobasal were seen. Examination of the CSF showed a CSF cell count of 180/μl and a donor chimerism of 80%. Again we applied a systemic chemotherapy with high-dose cytarabine but unfortunately the performance state of the patient rapidly worsened and the patient died in aplasia after chemotherapy with progredient cerebral lesions. In patient 2, a lasting remission could be achieved by a combination of systemic high-dose cytarabine (only once), seven doses of intrathecal infusions of DL and later on nilotinib. No therapy associated side effects were present over a period of 17 months.
Patient 3 received two infusions of intrathecal DL suffering from a leptomeningeal relapse of AML 13 years after diagnosis and 5 years after allo SCT. Under initial therapeutic intervention he developed intra-and extracerebral chloroma leading to a change of the treatment regimen. Although combining systemic chemotherapy and local irradiation of the chloroma, a complete remission could not be achieved. The patient died 6 months later in progressing AML (chloroma intraand extracerebral, bone marrow relapse). Concerning the application of intrathecal DL we could not observe any acute side effects.
So far, just one case with suspected refractory lymphomatous meningitis is described in which intrathecal infusions of DL were performed [14] . Because of the lacking experience with this experimental approach, we were not able to estimate possible side effects in advance. Firstly, there were concerns about direct inflammatory reactions after application. To avoid or reduce monocyte derived cytokine reactions we applied a CD14 depletion as described recently [15] . Whether this preparation is really necessary remains to be determined in future studies. Secondly, we were afraid of an induction of a cerebral GvHD reaction after allo SCT. Reviewing the literature there is no evident opinion regarding this topic. CNSassociated neurologic complications like cerebrovascular events, encephalitis or leukencephalopathy are mainly caused by drug toxicity, infections due to immunosuppression or bleeding in thrombocytopenia. Neurologic symptoms associated with a systemic GVHD are mainly neuromuscular syndromes or lesions of peripheral nerves in the presence of skin changes, e.g., due to sclerodermic GVHD [16] . In rare cases a CNS angiitis was associated with a chronic GVHD [17] . These observations are also underlined by data of murine BMT models [18] . An onset of the CNS angiitis is reported for up to 2 years after allo SCT, so that the observation period might not be long enough to evaluate any cerebral GVHD effects in our patients. Thirdly, we could not observe any infections like, e.g., meningitis or encephalitis caused by the treatment procedure with cells prepared under GMP conditions over a period up to 17 months.
Regarding the efficacy of intrathecal application of DL, no definite conclusion can be drawn. Additional treatments (including cytarabine, liposomal cytarabine, and nilotinib), used in a situation with poor prognosis and no established therapy, makes it difficult to determine exactly the impact of the effect of the DL treatment. Whether the transient absence of CSF cell count is still an effect of initial treatment or if there is a prelongation due to the sequentially used DL transfusions (in patient 1 with a decrease of the donor chimerism in the CSF and in patient 2 with an increase) must remain open. Furthermore, the efficacy of the DL depends on the track of T lymphocytes in and out the CSF. Whether the CSF is a hostile place for T lymphocytes and how many and which subsets of the T lymphocytes could act in the CSF is unsolved up to date [19] [20] [21] . From our data, we could only conclude that 1 week after the application of 6×10 6 cells less than 2.5% of these cells were detectable in the CSF at the location of infusion (assuming a homogenous distribution in a CSF volume of 150 ml). Of course we could not rule out that a considerable amount of T cells is attached to the meninges.
The intrathecal application of DL still is an experimental approach for patients with poor prognosis. Nevertheless, the application of in total 16 doses up to 1×10 7 cells showed no acute or delayed toxic side effects over an observation period of 17 months. This approach should merit further investigations in a multicenter trial accompanied by studies to track the T lymphocytes and determine still possible side effects to enhance the therapeutic options in the case of a leptomeningeal relapse after allo SCT. If direct applications of T lymphocytes in the CSF remain a feasible option as reported here in three patients, the treatment might not only include hematologic but also neurologic diseases.
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